Better blood sugar control in individuals with insulin resistance
Zero cases of medullary thyroid cancer reported Zero cases of C-cell hyperplasia detected No clinically significant changes in calcitonin levels observed These findings align with what researchers have seen across the entire GLP-1 medication class
GLP-1 receptor agonists have reshaped how clinicians and researchers think about metabolic disease, revealing a hormone system that links appetite, reward, emotion, inflammation and cardiovascular health
Retatrutide appears to have a similar safety profile to other GLP-1 medications: No increased risk of pancreatitis in trials so far No hepatotoxicity signals (liver damage) No cases of ketoacidosis Serious adverse events were rare (2.5% of participants) The trials are ongoing, so we'll learn more about long-term safety
Hunger can sneak up fast and feel awful when it does
However, the incidence of clinically meaningful muscle wasting under GLP-1RA therapy remains to be determined through prospective studies with standardized assessment methods
02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
